Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma

Abstract Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients. This is the first study to assess the expression of programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) in FH-RCC. Formalin-fixed paraffin-embedded samples from 13...

Full description

Saved in:
Bibliographic Details
Published in:Annals of diagnostic pathology 2017-08, Vol.29, p.17-22
Main Authors: Alaghehbandan, Reza, Stehlik, Jan, Trpkov, Kiril, Magi-Galluzzi, Cristina, Mundo, Enric Condom, Foix, Maria Pane, Berney, Daniel, Sibony, Mathilde, Suster, Saul, Agaimy, Abbas, Montiel, Delia Perez, Pivovarcikova, Kristyna, Michalova, Kvetoslava, Daum, Ondrej, Ondic, Ondrej, Rotterova, Pavla, Dusek, Martin, Hora, Milan, Michal, Michal, Hes, Ondrej
Format: Article
Language:English
Subjects:
Adult
B7-H1 Antigen - metabolism
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - pathology
Disease-Free Survival
Female
Fumarate Hydratase - deficiency
Fumarate Hydratase - metabolism
Humans
Immunohistochemistry - methods
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Lymphocytes, Tumor-Infiltrating - metabolism
Lymphocytes, Tumor-Infiltrating - pathology
Male
Middle Aged
Pathology
Programmed Cell Death 1 Receptor - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients. This is the first study to assess the expression of programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) in FH-RCC. Formalin-fixed paraffin-embedded samples from 13 FH-RCCs collected in an international multi-institutional study, were evaluated by immunohistochemistry (IHC) for PD-1/PD-L1 reactivity in tumor cells and tumor infiltrating lymphocytes (TILs). PD-1/PD-L1 expression was further evaluated by qPCR. By IHC, PD-1 was negative in tumor cells in all 13 cases. PD-L1 was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively. In TILs, PD-1 was positive in 1/13, weak positive in 3/13, and negative in 9/13 cases. In TILs, PD-L1 was weak positive by IHC in 5/13, and negative in 8/13 cases, respectively. qPCR confirmed the result for 2 of 3 IHC weak positive PD-1 samples. Of 7 IHC weak positive samples (in tumor cells), PD-L1 mRNA was detected in all 7 tumors. Conclusions The majority of FH-RCCs did not express PD-1/PD-L1 by IHC, which was confirmed by molecular analysis. PD-1/PD-L1 expression in FH-RCC is restricted to a proportion of cases which may benefit from targeted therapies.
ISSN:1092-9134
1532-8198
DOI:10.1016/j.anndiagpath.2017.04.007